As a consultant in the world of financial services, I believe that transition risks, and litigation risks for those institutions that fail to transition quickly enough, are the immediate threat – but it is not possible to rule out that a combination could lead to systemic risk that fundamentally changes the financial service industry.  Indeed, […]

Learning outcomes: Illustrate the need to broaden the definition of value beyond GDP. Distinguish the broad assets that are likely to prove profitable and resilient in a net zero economy from those that are likely to be devalued or stranded. In this journal entry, you are encouraged to reflect on where your organisation places value […]

When thinking of investments that need to be made for our organisation to remain profitable in the net zero transition I highlight the following points:Lending portfolio while our loan book nowadays still covers many outstanding loans that do not faciliate climate stability (by financing GHG emissing activities) and a healthy ecosystem, we need to steer our […]

I also work in consultancy and echo those points. Significant investments are being made in hiring sustainability professionals, training and upskilling on net zero, partnerships and building digital tools to support corporate and government clients in their net zero transition. This opens the business to the net zero advisory market to increase market share and […]

Financial profit is not directly applicable to a public hospital or a public healthcare system.  If we define public service profitability as the ability to see more patients, prioritised by clinical need, at the right time and the right place, then the discussion is more relevant. The retooling of the public health systems, utilising the […]

To remain profitable while transitioning to net-zero pharmaceutical companies need to invest into the following aspects:  Development of continous manufacturing processes and facilities to reduce waste which is sustainable itself and at the same time usually more profitable than manufacturing batch wise [1, 2] Centralization of drug manufacturing by pulling together as many manufacturing steps […]